Experimental HIV vaccine shows promise in early safety trial

NCT ID NCT06253533

Completed Disease control Sponsor: Immuno Cure Holding (HK) Limited Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a therapeutic DNA vaccine called ICVAX in 45 people with HIV who were already stable on antiretroviral therapy (ART). The goal was to see if the vaccine is safe and whether it can boost the immune system to better control the virus. Participants received different doses of the vaccine or a placebo, and researchers monitored side effects and immune responses for up to 60 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ICVAX (HIV therapeutic DNA vaccine)
What this could lead to: If successful, this could point toward a way to help the immune system control HIV without daily medication.
What could go wrong: This is a very early Phase 1 trial with only 45 people, so it is mainly checking safety. It may not show strong immune effects or lead to a functional cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUMAN IMMUNODEFICIENCY VIRUS HUMAN IMMUNODEFICIENCY VIRUS I INFECTION

Contacts and locations

Locations

Shenzhen Third People's Hospital

Shenzhen, Guangdong, 518112, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.